Skip to content

Clinical multicenter study of ICP guided 3D print-assisted minimally invasive treatment of hypertensive supratentorial intracerebral hemorrhage

Clinical multicenter study of ICP guided 3D print-assisted minimally invasive treatment of hypertensive supratentorial intracerebral hemorrhage

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055647
Enrollment
Unknown
Registered
2022-01-15
Start date
2022-03-01
Completion date
Unknown
Last updated
2023-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive supratentorial intracerebral hemorrhage

Interventions

experimental group:ICP guided 3D print-assisted minimally invasive treatment

Sponsors

ICU of Neurosurgery, Henan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged >18 years; 2. Patients admitted to hospital within 24 hours after onset; 3. Those who met the HICH clinical diagnostic criteria formulated by the 4th National Academic Conference on Cerebrovascular Diseases and were confirmed by head CT examination; 4. The amount of supratentorial blood loss was 20-40 mL; (The hematoma volume was estimated by head CT image within 24 h of onset, and the formula was V=A×B×C/2, where A was the maximum diameter at the level of maximum bleeding, B was the maximum diameter perpendicular to this, and C was the depth of vertical hematoma); 5. Informed consent of patients and their families.

Exclusion criteria

Exclusion criteria: 1. Traumatic cerebral hemorrhage; 2. Preoperative cerebral hernia; 3. Bleeding caused by rupture of cerebral aneurysm, cerebral venous malformation, intracranial tumor, amyloidosis, vasculitis, traumatic factors, cerebral infarction and after embolus and other clear causes; 4. Patients who had undergone surgical operations in other hospitals before admission; 5. Patients with multiple organ failure; 6. Patients with systemic infectious diseases; 7. Complicated with malignant tumor, blood system diseases, immune system diseases; 8. Patients with mental diseases and cognitive dysfunction; 9. Patients with incomplete basic information and those who have dropped out.

Design outcomes

Primary

MeasureTime frame
Clinical effect;

Countries

China

Contacts

Public ContactFengguang

Henan Provincial People's Hospital

fengguang@zzu.edu.cn+86 18903711799

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026